Business, energy, technology, markets and global industry news from Business News Today

hematology

PharmaDeviceNews hematology
Pharma & Biotech

PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera

Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.

Read More
Incyte’s acquisition of Vega Therapeutics adds the Phase 3 monoclonal antibody VGA039 to its hematology pipeline, strengthening its strategy in von Willebrand disease treatment. Representative image.
Pharma & Biotech

Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy

Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.

Read More
Cellares FDA PreCheck selection puts automated cell therapy manufacturing under early review
Pharma & Biotech

Cellares enters FDA PreCheck as Cell Shuttle moves from automation promise to regulatory proof

Find out how Cellares’ FDA PreCheck selection could reshape automated cell therapy manufacturing while leaving product approval risks intact.

Read More
Representative image: Laboratory research into blood-clotting disorders highlights Star Therapeutics’ VGA039 programme as complete Phase 1/2 von Willebrand disease data head to ISTH 2026.
Pharma & Biotech

Why Star Therapeutics’ complete VGA039 dataset matters for the future of von Willebrand disease care

See why Star Therapeutics’ complete VGA039 data at ISTH 2026 could reshape von Willebrand disease prophylaxis and Incyte’s strategy.

Read More
Representative image showing blood cancer clinical research and treatment review, reflecting Incyte’s tafasitamab frontMIND trial update in high-risk diffuse large B-cell lymphoma.
Pharma & Biotech

Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?

Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.

Read More
Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More
Representative image of hematology research and blood sample analysis, reflecting AbbVie’s long-term Venclexta data in first-line chronic lymphocytic leukemia treatment.
Pharma & Biotech

AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus

Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.

Read More
Representative image: A clinician reviews blood disorder data in a hospital setting, reflecting Johnson & Johnson’s IMAAVY Phase 2/3 results and the growing focus on FcRn-targeted treatment for warm autoimmune hemolytic anemia.
Pharma & Biotech

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.

Read More
Representative image: An oncologist reviews lymphoma scan data in a clinical setting as Incyte’s tafasitamab combination shows improved progression-free survival in high-risk diffuse large B-cell lymphoma, raising new questions about the future of first-line DLBCL treatment.
Pharma & Biotech

Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Read More